Investigating how a specific therapy affects immune cells in inflammatory bowel disease.
DCs as clinical targets of anti-integrin therapy in IBD
This study is looking at how a treatment called vedolizumab helps people with inflammatory bowel disease (like Crohn's disease and ulcerative colitis) by examining certain immune cells in their blood and colon, with the goal of figuring out who might benefit the most from this therapy and finding better ways to manage their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10993147 on NIH RePORTER |
What this research studies
This research focuses on understanding how the anti-integrin therapy vedolizumab works in patients with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. The researchers aim to analyze dendritic cells from the blood and colon of IBD patients to see how these cells respond to the therapy and how this relates to inflammation. By observing these immune cells, the study hopes to improve predictions about who will benefit from the treatment and to develop new strategies for managing IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who are currently receiving or considering treatment with vedolizumab.
Not a fit: Patients who do not have inflammatory bowel disease or those who are not eligible for vedolizumab therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment options and improved outcomes for patients with inflammatory bowel disease.
How similar studies have performed: Previous research has shown promising results with anti-integrin therapies in IBD, but this specific focus on dendritic cells is a novel approach.
Where this research is happening
Seattle, United States
- Benaroya Research Inst at Virginia Mason — Seattle, United States (Active)
Researchers
- Principal investigator: Lord, James Daniel — Benaroya Research Inst at Virginia Mason
- Study coordinator: Lord, James Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.